Simple Blood Test Can Predict Dementia Risk
By LabMedica International staff writers Posted on 16 Feb 2015 |
Image: Three dimensional structure of apolipoprotein E (APOE) (Photo courtesy of the Protein Data Bank).
A new biomarker has been identified that can predict the risk of developing dementia by way of a simple blood test which in the long term could mean better prevention and at least postponement of the illness and at best evading the development all together.
The apolipoprotein E (APOE) ε4 allele is a major genetic risk factor for Alzheimer disease and dementia; however, it remains unclear whether plasma levels of apoE confer additional risk. Prevalence increases in step with aging, and as people's life years are continually on the rise in most countries, there is also an increasing need to be able to identify the citizens who are at the greatest risk of suffering dementia.
Scientists at the University of Copenhagen (Denmark) enrolled 75,708 participants from the general population; and tested whether low plasma levels of apoE at study enrollment were associated with increased risk of future Alzheimer disease and all dementia, and whether this association was independent of ε2/ε3/ε4 APOE genotype.
Multifactorial adjusted hazard ratios (HRs) for Alzheimer disease and all dementia increased from the highest to the lowest apoE tertile. Multifactorial adjusted HRs for lowest versus highest tertile were 2.68 for Alzheimer disease and 1.80 for all dementia. After further adjustment for ε2/ε3/ε4 APOE genotype, plasma apoE tertiles remained associated with Alzheimer disease and all dementia. Plasma apoE tertiles did not interact with ε2/ε3/ε4 APOE genotype on risk of Alzheimer disease or all dementia. In a subanalysis, the -219G>T GT promoter genotype, associated with low plasma apoE levels, remained significantly associated with increased risk of Alzheimer disease after adjustment for ε2/ε3/ε4 APOE genotype.
The authors concluded that low plasma levels of apoE are associated with increased risk of future Alzheimer disease and all dementia in the general population, independent of ε2/ε3/ε4 APOE genotype. This is clinically relevant, because no plasma biomarkers are currently implemented. Hence, plasma levels of apoE may be a new, easily accessible preclinical biomarker. Ruth Frikke-Schmidt MD, PhD, the senior author of the study said, “The blood test will help provide a more precise risk evaluation of a citizen's risk of developing dementia later in life. Thus the citizens at the greatest risk of developing the illness are more easily identified than at present. The blood test will enable an earlier and more focused prevention effort, thus prolonging the onset of the illness and raising the individual's quality of life.” The study was published in the February 2015 issue of the journal Annals of Neurology.
Related Links:
University of Copenhagen
The apolipoprotein E (APOE) ε4 allele is a major genetic risk factor for Alzheimer disease and dementia; however, it remains unclear whether plasma levels of apoE confer additional risk. Prevalence increases in step with aging, and as people's life years are continually on the rise in most countries, there is also an increasing need to be able to identify the citizens who are at the greatest risk of suffering dementia.
Scientists at the University of Copenhagen (Denmark) enrolled 75,708 participants from the general population; and tested whether low plasma levels of apoE at study enrollment were associated with increased risk of future Alzheimer disease and all dementia, and whether this association was independent of ε2/ε3/ε4 APOE genotype.
Multifactorial adjusted hazard ratios (HRs) for Alzheimer disease and all dementia increased from the highest to the lowest apoE tertile. Multifactorial adjusted HRs for lowest versus highest tertile were 2.68 for Alzheimer disease and 1.80 for all dementia. After further adjustment for ε2/ε3/ε4 APOE genotype, plasma apoE tertiles remained associated with Alzheimer disease and all dementia. Plasma apoE tertiles did not interact with ε2/ε3/ε4 APOE genotype on risk of Alzheimer disease or all dementia. In a subanalysis, the -219G>T GT promoter genotype, associated with low plasma apoE levels, remained significantly associated with increased risk of Alzheimer disease after adjustment for ε2/ε3/ε4 APOE genotype.
The authors concluded that low plasma levels of apoE are associated with increased risk of future Alzheimer disease and all dementia in the general population, independent of ε2/ε3/ε4 APOE genotype. This is clinically relevant, because no plasma biomarkers are currently implemented. Hence, plasma levels of apoE may be a new, easily accessible preclinical biomarker. Ruth Frikke-Schmidt MD, PhD, the senior author of the study said, “The blood test will help provide a more precise risk evaluation of a citizen's risk of developing dementia later in life. Thus the citizens at the greatest risk of developing the illness are more easily identified than at present. The blood test will enable an earlier and more focused prevention effort, thus prolonging the onset of the illness and raising the individual's quality of life.” The study was published in the February 2015 issue of the journal Annals of Neurology.
Related Links:
University of Copenhagen
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans